Viridian Therapeutics, Inc.\DE - Common Stock (VRDN)
CUSIP: 92790C104
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 95,489,675
- Total 13F shares
- 86,940,196
- Share change
- +17,259,450
- Total reported value
- $1,978,662,594
- Put/Call ratio
- 76%
- Price per share
- $22.75
- Number of holders
- 163
- Value change
- +$415,185,793
- Number of buys
- 106
- Number of sells
- 56
Quarterly Holders Quick Answers
What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.\DE - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92790C104:
Top shareholders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
10%
|
9,573,348
|
$124,549,258 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
5%
|
4,773,622
|
$62,104,822 | — | 30 Jun 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
4.1%
|
3,923,849
|
$51,049,275 | — | 30 Jun 2024 | |
| VR Adviser, LLC |
13F
|
Company |
4.1%
|
3,882,671
|
$50,513,550 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
3,345,731
|
$43,527,961 | — | 30 Jun 2024 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
3.5%
|
3,307,945
|
$43,036,364 | — | 30 Jun 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
3%
|
2,896,349
|
$37,681,500 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.9%
|
2,772,379
|
$36,068,651 | — | 30 Jun 2024 | |
| Commodore Capital LP |
13F
|
Company |
2.6%
|
2,528,032
|
$32,889,696 | — | 30 Jun 2024 | |
| Frazier Life Sciences Public Fund, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,505,200
|
$31,609,200 | — | 23 Sep 2021 | |
| Novo Holdings A/S |
13F
|
Company |
2.1%
|
2,000,000
|
$26,020,000 | — | 30 Jun 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
2.1%
|
1,998,192
|
$25,996,478 | — | 30 Jun 2024 | |
| Fairmount Funds Management LLC |
13F
|
Company |
1.9%
|
1,845,813
|
$24,014,027 | — | 30 Jun 2024 | |
| Kynam Capital Management, LP |
13F
|
Company |
1.8%
|
1,750,000
|
$22,767,500 | — | 30 Jun 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
1.8%
|
1,678,207
|
$21,833,473 | — | 30 Jun 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.7%
|
1,631,828
|
$21,230,082 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
1,411,360
|
$18,364,886 | — | 30 Jun 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.5%
|
1,392,925
|
$18,121,954 | — | 30 Jun 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.1%
|
1,022,104
|
$13,297,573 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1%
|
999,941
|
$13,009,233 | — | 30 Jun 2024 | |
| Yiheng Capital Management, L.P. |
13F
|
Company |
0.99%
|
948,130
|
$12,335,171 | — | 30 Jun 2024 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.93%
|
889,198
|
$11,568,466 | — | 30 Jun 2024 | |
| Jonathan Violin |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
720,110
mixed-class rows
|
$10,099,005 | — | 02 Feb 2023 | |
| S.c.a. Candriam |
13F
|
Individual |
0.79%
|
749,804
|
$9,754,495 | — | 30 Jun 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.77%
|
736,595
|
$9,583,101 | — | 30 Jun 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.65%
|
620,000
|
$8,066,200 | — | 30 Jun 2024 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.63%
|
605,816
|
$7,881,666 | — | 30 Jun 2024 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.62%
|
587,708
|
$7,646,081 | — | 30 Jun 2024 | |
| Eversept Partners, LP |
13F
|
Company |
0.59%
|
567,487
|
$7,383,006 | — | 30 Jun 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.55%
|
526,700
|
$6,852,367 | — | 30 Jun 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.52%
|
500,000
|
$6,505,000 | — | 30 Jun 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.52%
|
498,403
|
$6,484,224 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.51%
|
483,921
|
$6,295,812 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.5%
|
479,881
|
$6,243,251 | — | 30 Jun 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.45%
|
430,596
|
$5,602,054 | — | 30 Jun 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.44%
|
419,820
|
$5,461,858 | — | 30 Jun 2024 | |
| Scott Dunseth Myers |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
259,500
|
$5,449,500 | — | 12 Apr 2023 | |
| Woodline Partners LP |
13F
|
Company |
0.42%
|
400,915
|
$5,215,904 | — | 30 Jun 2024 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.41%
|
395,497
|
$5,145,415 | — | 30 Jun 2024 | |
| EAGLE ASSET MANAGEMENT INC |
13F
|
Company |
0.39%
|
373,462
|
$4,933,433 | — | 30 Jun 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.37%
|
349,631
|
$4,548,705 | — | 30 Jun 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.36%
|
340,000
|
$4,423,400 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.34%
|
320,570
|
$4,170,620 | — | 30 Jun 2024 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.31%
|
300,000
|
$3,903,000 | — | 30 Jun 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.3%
|
284,044
|
$3,695,413 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.26%
|
247,600
|
$3,221,276 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
230,376
|
$2,997,192 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.24%
|
228,182
|
$2,968,648 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.22%
|
210,677
|
$2,740,907 | — | 30 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
208,676
|
$2,714,870 | — | 30 Jun 2024 |
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) as of Q3 2024
As of 30 Sep 2024,
Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) was held by
163 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
86,940,196 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., VANGUARD GROUP INC, VR Adviser, LLC, Deep Track Capital, LP, Fairmount Funds Management LLC, Paradigm Biocapital Advisors LP, PERCEPTIVE ADVISORS LLC, COMMODORE CAPITAL LP, and Kynam Capital Management, LP.
This page lists
163
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
137
Q3 2024 holders
163
Holder diff
26
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.